Ascendis Pharma A/S (NASDAQ:ASND) Receives $191.57 Average Target Price from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average rating of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $191.57.

Several brokerages have commented on ASND. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Oppenheimer cut their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. UBS Group assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. TD Cowen reduced their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th.

Ascendis Pharma A/S Price Performance

ASND opened at $129.41 on Monday. The firm has a market capitalization of $7.85 billion, a price-to-earnings ratio of -16.02 and a beta of 0.64. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The business has a 50 day simple moving average of $133.13 and a two-hundred day simple moving average of $132.65.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently bought and sold shares of the business. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $60,000. Janus Henderson Group PLC boosted its holdings in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.